{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:51:40Z","timestamp":1787064700506,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.vaccine.2009.05.010","type":"journal-article","created":{"date-parts":[[2009,5,28]],"date-time":"2009-05-28T05:02:18Z","timestamp":1243486938000},"page":"4718-4723","source":"Crossref","is-referenced-by-count":5,"title":["Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3"],"prefix":"10.1016","volume":"27","author":[{"given":"Matthias","family":"Piesche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Chapuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald G.","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schroers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2009.05.010_bib1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.1995.tb03297.x","article-title":"Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells","volume":"89","author":"Dengler","year":"1995","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.vaccine.2009.05.010_bib2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0092-8674(89)90752-6","article-title":"Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells","volume":"59","author":"Bories","year":"1989","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.vaccine.2009.05.010_bib3","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450","article-title":"Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells","volume":"88","author":"Molldrem","year":"1996","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.vaccine.2009.05.010_bib4","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood.V90.7.2529","article-title":"Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units","volume":"90","author":"Molldrem","year":"1997","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.vaccine.2009.05.010_bib5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2009.05.010_bib6","first-page":"2675","article-title":"A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia","volume":"59","author":"Molldrem","year":"1999","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.vaccine.2009.05.010_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.f.1774","article-title":"CD8+ T cell efficacy in vaccination and disease","volume":"14","author":"Appay","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2009.05.010_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-006-0194-y","article-title":"CD4 regulatory T cells in human cancer pathogenesis","author":"Knutson","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.010_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","article-title":"Regulatory T cells in cancer","volume":"108","author":"Beyer","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.vaccine.2009.05.010_bib10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-004-0653-2","article-title":"Tumor antigen-specific T helper cells in cancer immunity and immunotherapy","volume":"54","author":"Knutson","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2009.05.010_bib11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/0008-5472.CAN-04-2552","article-title":"Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation","volume":"65","author":"Voo","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.vaccine.2009.05.010_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(03)00359-5","article-title":"Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy","volume":"20","author":"Wang","year":"2004","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.vaccine.2009.05.010_bib13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.humimm.2007.03.007","article-title":"Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin","volume":"68","author":"Piesche","year":"2007","journal-title":"Hum Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2009.05.010_bib14","first-page":"2600","article-title":"Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells","volume":"62","author":"Schroers","year":"2002","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.vaccine.2009.05.010_bib15","first-page":"3260","article-title":"Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen","volume":"9","author":"Schroers","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.vaccine.2009.05.010_bib16","first-page":"4743","article-title":"Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes","volume":"9","author":"Schroers","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.vaccine.2009.05.010_bib17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ymeth.2004.06.002","article-title":"Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE","volume":"34","author":"Bian","year":"2004","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.010_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/bbrc.1996.0224","article-title":"Expression of the human autoantigen of Wegener's granulomatosis (PR3) in a baculovirus expression system","volume":"219","author":"Szymkowiak","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2009.05.010_bib19","series-title":"Gene delivery to mammalian cells: methods and protocols","year":"2003"},{"issue":"6","key":"10.1016\/j.vaccine.2009.05.010_bib20","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2002-01-0163","article-title":"CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia","volume":"100","author":"Scheibenbogen","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.vaccine.2009.05.010_bib21","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.4049\/jimmunol.152.9.4722","article-title":"Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis","volume":"152","author":"Williams","year":"1994","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.010_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2249.1995.tb03651.x","article-title":"Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG)","volume":"100","author":"Ballieux","year":"1995","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.010_bib23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.179.3.973","article-title":"Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis","volume":"179","author":"Zhang","year":"1994","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.vaccine.2009.05.010_bib24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00262-003-0455-y","article-title":"Identification of a MHC class-II restricted epitope in carcinoembryonic antigen","volume":"53","author":"Shen","year":"2004","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.010_bib25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2249.1998.00615.x","article-title":"T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission","volume":"112","author":"King","year":"1998","journal-title":"Clin Exp Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T06:25:30Z","timestamp":1684995930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09006781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":25,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0264410X09006781"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.05.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}